1073354-57-0Relevant articles and documents
THERAPEUTIC COMPOUNDS AND METHODS OF USE
-
Paragraph 0598; 0599; 0600, (2021/05/21)
The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
Rhodium-catalyzed dehydrogenative borylation of aliphatic terminal alkenes with pinacolborane
Morimoto, Masao,Miura, Tomoya,Murakami, Masahiro
supporting information, p. 12659 - 12663 (2015/10/28)
Aliphatic terminal alkenes react with pinacolborane at ambient temperature to afford dehydrogenative borylation compounds as the major product when iPr-Foxap is used as the ligand with cationic rhodium(I) in the presence of norbornene, which acts as the s
Efficient synthesis of diborylalkenes from alkenes and diboron by a new PSiP-pincer palladium-catalyzed dehydrogenative borylation
Takaya, Jun,Kirai, Naohiro,Iwasawa, Nobuharu
supporting information; experimental part, p. 12980 - 12983 (2011/10/04)
The efficient synthesis of various diborylalkenes such as 1,1-, trans-1,2-, and cyclic 1,2-diborylalkenes from alkenes and diboron was achieved for the first time. Selective preparation of di- and monoborylalkenes was also realized by the appropriate choi